Factors of unfavorable prognosis in stage I skin melanoma
K. S. Titov,
M. V. Sorokina,
T. A. Yakusheva,
E. Yu. Neretin,
A. A. Markin,
S. S. Lebedev,
D. N. Grekov https://doi.org/10.20340/vmi-rvz.2024.6.CLIN.4
- Р Р‡.МессенРТвЂВВВВВВВВжер
- РћРТвЂВВВВВВВВнокласснРСвЂВВВВВВВВРєРСвЂВВВВВВВВ
- LiveJournal
- Telegram
- ВКонтакте
- РЎРєРѕРїРСвЂВВВВВВВВровать ссылку
Full Text:
Abstract
Skin melanoma is one of the most malignant tumors and is responsible for 70.3% of deaths in the group of skin cancers in the Russian Federation. Skin melanoma is characterized by a steady increase in the incidence among the working-age population, both in Russia and abroad (annual increase in incidence is about 3–4%). At the moment, for stages I-II of skin melanoma, practitioners have been using only clinical (clinical form of melanoma, localization, gender, age, etc.) and standard pathomorphological prognostic factors for many years. For thin skin melanoma, the presence of ulceration, Breslow thickness, mitotic index, lymphovascular invasion, and presence of regression are the most significant prognostic biomarkers. The most informative predictors are needed to improve the stratification of patient prognosis. For a more accurate and individual prognosis, regular integration of already known clinical and morphological factors of the tumor with other prognostic characteristics, such as, for example, lymphovascular invasion, as well as with molecular genetic parameters, is necessary. A more accurate assessment of the risk of progression of "thin" melanoma of the skin stages IA-IB may in the future help the choice, application of new treatment approaches, as well as the frequency and volume of follow-up examinations by an oncologist.
About the Authors
K. S. Titov
Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin;
Peoples' Friendship University of Russia named after Patrice Lumumba
Russian Federation
Competing Interests:
Russian Federation
Konstantin S. Titov, Dr. Sci. (Med.), Professor, Leading Researcher; Professor of the Department of Oncology and Roentgenology named after Academician V.P. Kharchenko SPIN-code: 7795-6512
2-y Botkinskiy proezd, 5, Moscow, 125284;
6, Miklukho-Maclay St., Moscow, 117198
Competing Interests:
The authors declare no competing interests.
M. V. Sorokina
Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin
Russian Federation
Competing Interests:
Russian Federation
Margarita V. Sorokina, Oncologist, Acting Head of the Department of Diagnostics and Treatment of Breast and Reproductive System Diseases, Central Asian Oncology Center SPIN-code: 7883-1790
2-y Botkinskiy proezd, 5, Moscow, 125284
Competing Interests:
The authors declare no competing interests.
T. A. Yakusheva
Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin
Russian Federation
Competing Interests:
Russian Federation
Tat'yana A. Yakusheva, Head of the Oncology Department No. 1
2-y Botkinskiy proezd, 5, Moscow, 125284
Competing Interests:
The authors declare no competing interests.
E. Yu. Neretin
Samara Regional Clinical Oncology Dispensary;
Medical University Reaviz
Russian Federation
Competing Interests:
Russian Federation
Evgeniy Yu. Neretin, Dr. Sci. (Med.), oncologist of the highest category of the consultative department No. 1; associate professor of the department of surgery with a course in oncology Scopus Author ID: 57016832800; AuthorID: 6237266.
ul. Solnechnaya, 50, Samara, 443029;
227, Chapaevskaya St., Samara, 443001
Competing Interests:
The authors declare no competing interests.
A. A. Markin
A. S. Loginov Moscow Clinical Research Center
Russian Federation
Competing Interests:
Russian Federation
Aleksandr A. Markin, Oncologist, Chemotherapy Day Hospital Department
1/1, Novogireevskaya St., Moscow, 111123
Competing Interests:
The authors declare no competing interests.
S. S. Lebedev
Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin;
Russian Medical Academy of Continuous Professional Education
Russian Federation
Competing Interests:
Russian Federation
Sergey S. Lebedev, Dr. Sci. (Med.), Head of the Central Aesthetic and Orthopedic Surgery Department; Associate Professor of the Department of Surgery AuthorID: 936520.
2-y Botkinskiy proezd, 5, Moscow, 125284;
2/1 Barrikadnaya St., building 1, Moscow, 125993
Competing Interests:
The authors declare no competing interests.
D. N. Grekov
Moscow Multidisciplinary Scientific and Clinical Center named after S.P. Botkin;
Russian Medical Academy of Continuous Professional Education
Russian Federation
Competing Interests:
Russian Federation
Dmitriy N. Grekov, Cand. Sci. (Med.), Deputy Chief Physician for Oncology; Associate Professor of the Department of Surgery, Faculty of Surgery AuthorID: 989579
2-y Botkinskiy proezd, 5, Moscow, 125284;
2/1 Barrikadnaya St., building 1, Moscow, 125993
Competing Interests:
The authors declare no competing interests.
References
1. Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI et al; for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov;67(6):472-492. https://doi.org/10.3322/caac.21409 Epub 2017 Oct 13. PMID: 29028110; PMCID: PMC5978683.
2. Roncati L, Pusiol T, Piscioli F. Prognostic Predictors of Thin Melanoma in Clinico-Pathological Practice. Acta Dermatovenerol Croat. 2017 Jul;25(2):159-160. PMID: 28871933.
3. Tímár J, Ladányi A. Molecular Pathology of Skin Melanoma: Epidemiology, Differential Diagnostics, Prognosis and Therapy Prediction. Int J Mol Sci. 2022 May 11;23(10):5384. https://doi.org/10.3390/ijms23105384 PMID: 35628196; PMCID: PMC9140388.
4. Roncati L, Pusiol T, Piscioli F. Thin Melanoma: A Generic Term Including Four Histological Subtypes of Cutaneous Melanoma. Acta Dermatovenerol Croat. 2016 Dec;24(4):169-174. PMID: 28128089.
5. Keung EZ, Gershenwald JE. The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care. Expert Rev Anticancer Ther. 2018 Aug;18(8):775-784. https://doi.org/10.1080/14737140.2018.1489246 PMID: 29923435; PMCID: PMC7652033.
6. Claeson M, Baade P, Brown S, Soyer HP, Smithers BM, Green AC et al., Clinicopathological factors associated with death from thin (≤ 1•00 mm) melanoma. Br J Dermatol. 2020 Apr;182(4):927-931. https://doi.org/10.1111/bjd.18560 Epub 2019 Nov 24. PMID: 31562769.
7. Ruksha TG, Aksenenko MB, Shvetsova YuI. Molecular and pathomorphological prognostic markers for melanoma: Current approaches and prospects. Arkhiv Patologii. 2015;77(4):71 77. (In Russ.) https://doi.org/10.17116/patol201577471-77
8. Sentinel node biopsi procedure for melanom. Danske Multidisciplinære Cancer Grupper og Regionernes Kliniske Kvalitetsudviklingsprogram, 2021. https://www.melanoma.dk/assets/files/Melanoma_Guidelines_Sentinel_node_biopsi.pdf.
9. Ly CL, Blaha O, Wei W, Galan A, Kluger H, Ariyan S, et al. Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas. Front Oncol. 2023 Jan 6;12:1077226. https://doi.org/10.3389/fonc.2022.1077226 PMID: 36686728; PMCID: PMC9853390.
10. Homolak D, Šitum M, Čupić H. Clinico-pathological features of patients with melanoma and positive sentinel lymph node biopsy: a single institution experience. Acta Dermatovenerol Croat. 2015;23(2):122-129.
11. Richetta AG, Valentini V, Marraffa F, Paolino G, Rizzolo P, Silvestri V et al. Metastases risk in thin cutaneous melanoma: prognostic value of clinical-pathologic characteristics and mutation profile. Oncotarget. 2018 Aug 14;9(63):32173-32181. https://doi.org/10.18632/oncotarget.25864 PMID: 30181807; PMCID: PMC6114949.
12. Eguchi MM, Elder DE, Barnhill RL, Piepkorn MW, Knezevich SR, Elmore JG et al. Prognostic modeling of cutaneous melanoma stage I patients using cancer registry data identifies subsets with very-low melanoma mortality. Cancer. 2023 Jan 1;129(1):89-97. https://doi.org/10.1002/cncr.34490 Epub 2022 Nov 7. PMID: 36336975.
13. Leung B. Clinical and histopathologic risk factors for early-stage melanoma recurrence. J. Investig. Dermatol. 2022;142:S113. https://doi.org/10.1016/j.jid.2022.05.669
14. Jakub JW, Weaver AL, Meves A. Association of tumor molecular factors with in-transit metastasis in primary cutaneous melanoma. Int J Dermatol. 2022 Sep;61(9):1117-1123. https://doi.org/10.1111/ijd.16141 Epub 2022 Mar 5. PMID: 35246838; PMCID: PMC9391269.
15. Matheson JA, Te Marvelde L, Mailer S, Speakman D, Spillane J, Henderson MA et al. Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma. Melanoma Res. 2017 Feb;27(1):43-49. https://doi.org/10.1097/CMR.0000000000000302 PMID: 27753732.
16. Germano A, Cardili L, Carapeto FCL, Landman G. BRAFV600E and KIT immunoexpression in early-stage melanoma. An Bras Dermatol. 2019 Oct 17;94(4):458-460. https://doi.org/10.1590/abd1806-4841.20198349 PMID: 31644622; PMCID: PMC7007021.
17. Montagnani V, Benelli M, Apollo A, Pescucci C, Licastro D, Urso C, et al. Thin and thick primary cutaneous melanomas reveal distinct patterns of somatic copy number alterations. Oncotarget. 2016 May 24;7(21):30365-78. https://doi.org/10.18632/oncotarget.8758 PMID: 27095580; PMCID: PMC5058686.
18. Dessinioti C, Dimou N, Geller AC, Stergiopoulou A, Lo S, Keim U, et al. Distinct Clinicopathological and Prognostic Features of Thin Nodular Primary Melanomas: An International Study from 17 Centers. J Natl Cancer Inst. 2019 Dec 1;111(12):1314-1322. https://doi.org/10.1093/jnci/djz034 PMID: 30863861; PMCID: PMC6910161.
19. Theile H, Moore J, Dunn N, Cossio D, Forristal CE, Green AC, et al. Regional nodal metastasis and 5-year survival in patients with thin melanoma in Queensland: a population-based study. ANZ J Surg. 2020 Apr;90(4):503-507. https://doi.org/10.1111/ans.15804 Epub 2020 Mar 12. PMID: 32162780.
20. El Sharouni MA, Aivazian K, Witkamp AJ, Sigurdsson V, van Gils CH, Scolyer RA et al. Association of Histologic Regression With a Favorable Outcome in Patients With Stage 1 and Stage 2 Cutaneous Melanoma. JAMA Dermatol. 2021 Feb 1;157(2):166-173. https://doi.org/10.1001/jamadermatol.2020.5032 PMID: 33355600; PMCID: PMC7758823.
21. Naik PP. Role of Biomarkers in the Integrated Management of Melanoma. Dis Markers. 2021 Dec 30;2021:6238317. https://doi.org/10.1155/2021/6238317 PMID: 35003391; PMCID: PMC8739586.
22. Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005 Nov 1;23(31):8048-56. https://doi.org/10.1200/JCO.2005.02.0735 PMID: 16258103.
Review
For citations:
Titov K.S., Sorokina M.V., Yakusheva T.A., Neretin E.Yu., Markin A.A., Lebedev S.S., Grekov D.N. Factors of unfavorable prognosis in stage I skin melanoma. Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2024;14(6):73-77. (In Russ.) https://doi.org/10.20340/vmi-rvz.2024.6.CLIN.4
Views:
89
ISSN 2226-762X (Print)
ISSN 2782-1579 (Online)
ISSN 2782-1579 (Online)
Email this article 